

Improved Localization for 2-Hydroxyglutarate Detection at 3 T Using Long-TE Semi-LASER

Adam Berrington¹, Natalie L. Voets¹, Puneet Plaha², Sarah J. Larkin³, James Mccullagh⁴, Richard Stacey², Muhammed Yildirim⁵, Christopher J. Schofield⁴, Peter Jezzard¹, Tom Cadoux-Hudson², Olaf Ansorge³, and Uzay E. Emir¹

¹Nuffield Department of Clinical Neurosciences, FMRIB Centre, John Radcliffe Hospital, University of Oxford, Oxford; ²Department of Neurosurgery, John Radcliffe Hospital, Oxford University Hospitals NHS Trust, Oxford; ³Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford; ⁴Department of Chemistry, University of Oxford, Oxford; and ⁵Advanced Diagnostic Imaging, Philips Healthcare, The Netherlands

Corresponding Author:

Uzay E. Emir, Nuffield Department of Clinical Neurosciences, FMRIB Centre, John Radcliffe Hospital, Oxford, OX3 9DU;
E-mail: uzay.emir@ndcn.ox.ac.uk

Key Words: 2-HG, semi-LASER, 3T, MRS, glioma

Abbreviations: 2-hydroxyglutarate (2-HG), isocitrate dehydrogenase (IDH), signal-to-noise ratio (SNR), wild-type (WT), to be confirmed (TBC), glutamate (Glu), glutamine (Gln), point-resolved spectroscopy (PRESS), lactate (Lac), magnetic resonance spectroscopy (MRS), Versatile Simulation, Pulses and Analysis (VeSPA), magnetic resonance (MR), Cramér–Rao lower bound (CRLB)

ABSTRACT

2-hydroxyglutarate (2-HG) has emerged as a biomarker of tumor cell isocitrate dehydrogenase mutations that may enable the differential diagnosis of patients with glioma. At 3 T, detection of 2-HG with magnetic resonance spectroscopy is challenging because of metabolite signal overlap and spectral pattern modulation by slice selection and chemical shift displacement. Using density matrix simulations and phantom experiments, an optimized semi-LASER scheme (echo time = 110 milliseconds) considerably improves localization of the 2-HG spin system compared with that of an existing point-resolved spectroscopy sequence. This results in a visible 2-HG peak in the in vivo spectra at 1.9 ppm in the majority of isocitrate dehydrogenase-mutated tumors. Detected concentrations of 2-HG were similar using both sequences, although the use of semi-LASER generated narrower confidence intervals. Signal overlap with glutamate and glutamine, as measured by pairwise fitting correlation, was reduced. Lactate was readily detectable across patients with glioma using the method presented here (mean Cramér–Rao lower bound: 10% ± 2%). Together with more robust 2-HG detection, long-echo time semi-LASER offers the potential to investigate tumor metabolism and stratify patients in vivo at 3 T.

INTRODUCTION

The Promise of 2-HG

Personalized medication in the treatment of cancer requires the discovery of reliable biomarkers and the development of tools capable of differential diagnosis according to genetic subtypes. In brain tumors, accumulation of the “oncometabolite” D-2-hydroxyglutarate (2-HG) in the majority (~80%) of grades 2–3 gliomas and secondary glioblastomas (1, 2) is potentially such a biomarker. 2-HG is produced as a metabolic product of somatic mutations in genes encoding for isocitrate dehydrogenase (IDH) (2), particularly *IDH1* and *IDH2*, which encode for enzymes located in the cytosol and mitochondria, respectively. Recent studies have shown that patients with glioma with the IDH mutation have improved prognoses compared with those without (3, 4), and stratification by IDH mutation status and its biochemical consequences may offer new opportunities for the diagnosis, monitoring, and treatment of patients with glioma (5, 6). Therefore, accurate, noninvasive, and robust determination of 2-HG in tumors, as a surrogate marker for IDH mutation

status is key for presurgical diagnosis and subsequent monitoring of treatment efficacy and relapse.

2-HG as a Detectable Molecule

2-HG is detectable in brain tumors using magnetic resonance spectroscopy (MRS), initially using ex vivo high-resolution magic-angle spinning (7), thereby enabling the possibility of IDH identification without the need for invasive surgical biopsy. However, the detection of 2-HG using in vivo MRS brings with it several technical challenges. 2-HG has a strongly coupled AMNPQ spin system with 5 proton resonances (H2, H3, H3', H4, and H4') at chemical shifts of 4.02, 1.83, 1.98, 2.22, and 2.27 ppm at pH 7 (8) (Figure 1). Pope et al., in their initial work, used a short-echo time (TE = 30 milliseconds) proton MRS point-resolved spectroscopy (PRESS) (9, 10) sequence at 3 T to demonstrate 2-HG detection in vivo (11). However, spectral overlap between the 2-HG peak at 2.25 ppm (H4 and H4') and glutamate (Glu) and glutamine (Gln) resonances, in addition to the large baseline offset at short TE, led to a large false-positive detection rate for 2-HG. Interestingly, even at 9.4 T (where spectral resolution is ~3 times greater), accurate short-TE detection of 2-HG




Figure 1. Proton spectral pattern of 2-hydroxyglutarate (2-HG) and corresponding hydrogen spins. Shown here are 3 T (127.7 MHz) with 1 Hz line broadening, 8912 spectral points, and 6 kHz spectral width. Only contributions from non-exchangeable, J-coupled spins at positions 2, 3, and 4 are visible (8).

in mouse models remains challenging (12), although recent success has been reported in patient studies (13). To overcome this spectral overlap issue, *in vivo* 2-dimensional (2D) correlation spectroscopy and spectral editing with MEGA-LASER were proposed by Andronesi et al. (14). However, such techniques can suffer from longer scan times, which are challenging to implement in clinical studies. J-editing with MEGA-LASER on the H2 and H3/H3' scalar-coupled spins results in a difference spectrum with clear 2-HG peak at 4.02 ppm; however, in addition to the dependence of such sequences on editing efficiency, localized shimming as used in single-voxel MRS of tumors can introduce spurious water echoes around this chemical shift value (15), which could negatively influence difference spectra.

An alternative to these approaches is to use single-shot techniques with longer TE. Choi et al. optimized the timings of a PRESS sequence (TE = 97 milliseconds) to maximize the H4/H4' peak of 2-HG at 2.25 ppm among the Glu and Gln overlaps and differentiated between IDH-mutant and wild-type (WT) tumors with much higher accuracy than with short-TE PRESS (16, 17). It is well understood that the spectra of J-coupled metabolites are susceptible to signal modulation using PRESS localization, with imperfect slice selection profiles and chemical shift displacement artifact arising from the use of narrow-bandwidth refocusing pulses (18, 19). For 2-HG, this manifests as signal loss at the H3/H3' resonance (1.9 ppm) when using the 97 millisecond PRESS sequence (16).

2-HG Detection with Reduced Chemical Shift Displacement

Detection of 2-HG at 3 T may benefit from the presence of this peak at 1.9 ppm. However, this chemical shift position also lies near Glu and Gln resonances, as well as near a γ -aminobutyric acid (GABA) resonance at 1.89 ppm, and is adjacent to the N-acetylaspartate (NAA) peak at 2.01 ppm (20). Recently, an optimized semi-LASER sequence (TE = 110 milliseconds) was proposed for 2-HG detection at both 7 T and 3 T (21, 22), which, owing to increased spectral sensitivity at 7 T, is able to separate IDH1 and IDH2 mutants on the basis of spectral feature detection. This study investigates the benefit of broadband adiabatic refocusing pulses at 3 T by reducing loss of signal from the combination of poor slice localization and chemical shift displacement for the coupled spin system of 2-HG. Thus, our


optimized long-TE semi-LASER localization scheme (24) is compared with an existing PRESS sequence (TE = 97 milliseconds) to detect 2-HG at 3 T in phantom and *in vivo*. First, quantum mechanical density matrix simulations and phantom validations are performed using both semi-LASER and PRESS (TE = 97 milliseconds) schemes to assess the benefits of adiabatic localization on the 2-HG spectral profile. The sensitivity of the optimized method is then compared in a phantom before being tested *in vivo* in 11 patients with glioma with and without IDH mutation.

METHODOLOGY

TE Optimization of Semi-LASER

A semi-LASER localization scheme is optimized for the detection of the H3/H3' multiplet of 2-HG among the overlapping Glu and Gln resonances. The implementation of semi-LASER is symmetrical in the positioning of its 2 pairs of gradient-selective refocusing pulses (Figure 2) (23). The TE is defined by the duration of the 90° and 180° refocusing pulses; t_{90} and t_{180} ; and the interpulse durations, τ , such that, $\tau_1 = 0.78$, $\tau_2 = 1.56$, $\tau_3 = 1.56$, $\tau_4 = (TE - 4t_{180} - 2\tau_3)/2$ and $\tau_5 = TE - \tau_1 - \tau_2 - \tau_3 - \tau_4 - 4t_{180} - t_{90}/2$ in milliseconds. Therefore, the manipulation of the TE is equivalent to varying the onset time of the final refocusing pulse (τ_4) and readout (τ_5). The excitation pulse in this semi-LASER implementation is an hsinc 90° excitation (duration = 2.56 millisecond, bandwidth = 3.4 kHz), and refocusing is performed using adiabatic pulses (HS4 R25, duration = 4.5 milliseconds, and bandwidth = 5.5 kHz) (24). Frequency-selective localization is simulated for the overlapping spin systems of 2-HG, Glu, and Gln on the basis of previously reported chemical shifts and coupling constants (8, 20) using real refocusing pulse information and the GAMMA/PyGAMMA simulation library of Versatile Simulation, Pulses and Analysis (VeSPA) (25). The integrated signal intensity over a 15 Hz window centered on 1.91 ppm is shown for these 3 metabolites at increasing TE (Figure 3A). It can be seen that at TE = 110 milliseconds, the H3/H3' (1.9 ppm) peak has an upright lineshape, while overlapping signal contributions from both Glu and Gln are almost 0 (Figure 3, B and C). Signal yield of 2-HG is higher at short TE (42% at 40 milliseconds), although multiplet lineshapes and the similarity of the spectral patterns of Glu and Gln do not allow a clear distinction from 2-HG. Therefore, the

Figure 2. Pulse sequence diagram for semi-LASER. The total echo time (TE) is defined using interpulse delays τ ; timings are given in the text.



TE of semi-LASER was selected as 110 milliseconds to elucidate 2-HG from these overlaps.

Chemical Shift Simulations


For the analysis of the chemical shift displacement artifact and the effect of slice selection profile across refocusing directions on the detection of 2-HG, custom 2D quantum mechanical density matrix simulations were developed and written in Matlab (Mathworks, Inc., Natick, Massachusetts) (Pseudocode in Supplementary Materials [1]).

Several methods exist to simulate localized spectra, including simplified hard-pulse 4-compartment models, which solely account for different chemical shifts and J-modulated signals within the voxel (26), or tip-angle pulse profile models, which additionally characterize the effect of the imperfect transition bands of refocusing pulses (27). Importantly, the effect of the chemical shift and the J-evolution during a pulse is non-negligible when $1/J$ is comparable to the pulse duration (28). The strongest J-coupling in 2-HG, between the H4 and H4' spins (15.0 Hz), is $1/J_{44'} = 67$ milliseconds. For 2 PRESS Refoman6 refocusing pulses (duration = 13.2 milliseconds), this corre-

sponds to nearly 40% of the J-evolution time. Thus, our localized simulations account for coupling and chemical shift evolution during the refocusing pulses.

Density matrix product operators were calculated at each stage of the pulse sequence corresponding to Hamiltonians for J-coupling, radio frequency (RF) pulse tip, and chemical shift evolution. The previously shown asymmetrical PRESS sequences (16) ($TE = 97$ milliseconds; $TE_1 = 32$ milliseconds; and $TE_2 = 65$ milliseconds; Supplementary Materials [2]) with Refoman6 refocusing pulses (duration = 13.2 milliseconds; bandwidth = 1.24 kHz; maximum $B_1 = 13.4 \mu T$; number of points = 200) are compared with the optimized semi-LASER sequences ($TE = 110$ milliseconds) with full passage adiabatic refocusing pulses (HS4 R25 maximum $B_1 = 28 \mu T$; number of points = 511). The hsinc 90° pulse was selected for excitation in both sequences. In ideal simulations, the RF pulses are modeled as instantaneous hard pulses. For the fully localized simulations, the 90° excitation pulses remain hard with 0 duration; however, the 180° pulses are divided into a series of small hard-pulse operators interspersed with the J-evolution and spatially depen-

Figure 3. Optimization of semi-LASER TE for the detection of 2-HG. Signal integral as a function of the TE for 2-HG, glutamate (Glu) and glutamine (Gln) (A). Spectral profiles shown for 4 different TEs (B). Close up of 2-HG H3/H3' (1.9 ppm) resonance at 110 milliseconds with overlaps showing 15 Hz integration window (C). At 110 milliseconds, semi-LASER generates near zero overlap from Glu and Gln around 1.9 ppm.



dent chemical shift operators to simulate slice selection gradients. Crusher gradients are simulated as incremental $\pi/4$ rotations about the z-axis positioned around each refocusing pulse similar to previous work (29, 30). To match in vivo acquisition, the RF carrier frequency is set to 2.7 ppm, and all simulations are line-broadened to 6 Hz by multiplication with an exponential factor. The sampling frequency is set at 6 kHz, and a total of 8192 time points are sampled from the resulting free induction decay (FID).

2-HG was simulated, along with 20 other commonly observed metabolites. Spin systems were simulated on a 100×100 grid, with a resolution of 1% of the nominal voxel size. For larger spin systems ($N \geq 6$), the grid resolution was reduced to 20×20 resolution or 5% of the nominal voxel size to reduce computational time. Simulations were run on a computing cluster with a minimum 2.67 GHz processor and 64 GB RAM.

Sensitivity Phantom

To test the sensitivity of our method, a test phantom containing 6 bottles of varying 2-HG concentrations (66 ml) (or R,S- α -hydroxyglutaric acid, Sigma Aldrich, St. Louis, MO) was constructed. 10mM of glycine (Gly) was included in each bottle to act as a reference peak, having only a singlet resonance at 3.55 ppm (20). Concentrations of 2-HG were 0.1, 0.5, 1, 2, 5, and 8mM. Each bottle was buffered with phosphate-buffered saline, and average pH was measured to be 7.5 ± 0.1 . The larger bottle was filled with NaCl solution. Phantom measurements were acquired on a 3 T whole-body magnetic resonance (MR) Prisma system (Siemens, Erlangen, Germany) with a 32-channel receive array head coil. Voxels of $20 \times 20 \times 20 \text{ mm}^3$ volume were obtained and shimmed to second order using GRESHIM (31). Both PRESS (TE = 97 milliseconds) and optimized semi-LASER (TE = 110 milliseconds) spectra were acquired with VAPOR water suppression and outer volume saturation bands (32) at a TR of 3 seconds. RF pulses and timings were equivalent to those in simulations, and 128 transients were acquired for each bottle in the phantom together with an unsuppressed water reference used for eddy current correction.

In Vivo MRS

In total, 11 patients with glioma (male, 7; female, 4; age, 39 ± 11 years) underwent scanning with the optimized semi-LASER (TE = 110 milliseconds) sequence in addition to PRESS (TE = 97 milliseconds). Of those, 6 patients underwent scanning with semi-LASER only because of constraints during a time-sensitive MR protocol. Written and informed consent approved by the South Central-Oxford B National Research Ethics Committee was obtained from all participants. Scanning was performed before resection and histological confirmation in all but 1 patient (P08), who underwent only partial resection and whose residual tumor was scanned early postoperatively. To test both methods, 5 healthy volunteers (male, 2; female, 3; age, 28 ± 4 years) also underwent scanning with both sequences. Voxels of $20 \times 20 \times 20 \text{ mm}^3$ volume were acquired on 3 T whole-body MR Prisma/Trio systems, and the protocol remained identical to the phantom investigation with 64–96 transients collected in patients and 96 in healthy volunteers. An unsuppressed water scan was also collected for absolute quantification.

Immunohistochemistry and DNA Sequencing

Immunohistochemistry was performed on ($4 \mu\text{m}$) tissue sections to detect the R132H IDH mutation. Endogenous peroxidase activity was blocked and epitopes retrieved (autoclave, 121°C for 10 minutes in 10mM sodium citrate; pH 6.0). Visualization was achieved using Dako REAL EnVision/HRP, Rabbit/Mouse (ENV) kit (Dako), after incubation of sections with the primary antibody (IDH1 R132H, clone H09, Dianova, 1:100, overnight at 4°C). DNA sequencing was performed on regions of IDH1- and IDH2-containing codons 132 and 172, respectively (amplified with Polymerase chain reaction (PCR)). Products were examined using agarose gel separation and then purified (MinElute PCR Purification Kit, Qiagen). Sequencing reactions were achieved using BigDye Terminator chemistry and an ABI-3730 sequencer. The methodology is identical to that reported by Emir et al. (2016) (21).

Analysis

Basis sets are generated from the fully localized simulations for metabolite assignment with LCModel (33). The basis set includes 2HG, alanine (Ala), ascorbate (Asc), Asp, GABA, Cr+PCr (total creatine: tCr), Gln, Glu, Gly, myo-inositol (myo-Ins), lactate (Lac), NAA+NAAG (total NAA: tNAA), phosphocholine (PCho), phosphatidylethanolamine (PE), scyllo-inositol (scyllo-Ins), taurine (Tau), glucose (Glc), and glutathione (GSH). Individual spectra were corrected for frequency and eddy current. For quantification of absolute metabolite concentrations, an exponential scaling correction, based on the transverse decay rate, T2, was applied to the unsuppressed water reference (assuming a bulk water concentration of 55.5mM) using the average of recently published values in low- and high-grade tumors (150 milliseconds) (34) and was set to 83 milliseconds for healthy brain (35). A correction based on metabolite relaxation rates (T1 and T2) was not performed in this work. Thus, all reported absolute concentrations are semiquantitative in nature.


To assess the effect of overlaps on spectral fitting with the LCModel, correlation coefficients are reported as the average of the pairwise correlation between individual metabolite fits X and Y , $r_{X,Y}$. Signal-to-noise ratio (SNR) is reported as the LCModel output ratio of maximum signal height to $2 \times$ the root mean square of the fitting residual. In this work, 95% confidence intervals ($\approx 2 \times$ Cramér-Rao lower bound [CRLB]) are reported alongside the weighted mean of the absolute concentration values as described in the LCModel manual (33).

RESULTS

PRESS and Semi-LASER Localization

First, localization of the 2-HG H3/H3' multiplet was investigated using simulations of our optimized semi-LASER sequence (TE = 110 milliseconds) and the original PRESS (TE = 97 milliseconds) sequence (16) (Figure 4). The total integrated H3/H3' peak 2-HG intensity at 1.9 ppm, following 2D fully localized simulations (green), is shown at each position on the 200×200 simulated grid on the intensity maps in Figure 4A. A heterogeneous distribution of signal intensity at 1.9 ppm, which manifests as compartments of several distinct signal profiles, is seen using PRESS localization. In particular, there is a complete inversion of the 1.9 ppm peak within one of these compartments (Figure 4A (1)), accounting

Figure 4. 2-HG localization using point-resolved spectroscopy (PRESS) and semi-LASER. 2-dimensional (2D) grid simulation showing integrated H3/H3' peak intensity at 1.9 ppm (15 Hz window) for both sequences (A). 200 × 200 spatial grid size. Spectra taken from representative positions (1–3) within grids are shown alongside and show deviations from ideal pulse simulations. Total simulated 2-HG acquisition (ideal and localized) shown alongside data taken from phantom (black); Gly is also included (B). The H3/H3' resonance appears to be diminished using real refocusing pulses in PRESS because of large compartmental chemical shift displacement artifacts; however, it remains upright and close to the ideal with semi-LASER.



for ~19% of the total 2D voxel, which has acquired an antiphase signal characteristic compared with the ideal pulse simulation (gray). Only ~52% of the localized PRESS voxels contain a positive signal contribution at this shift value (Figure 4A (2)). However, a semi-LASER sequence displays a far superior slice selection profile and reduced chemical shift displacement artifact for the multiplet of H3/H3'. This is evident from the presence of a single, uniform compartment containing positive signal contribution, and it is almost identical to the ideal pulse simulations (Figure 4A (3)).

Figure 4B shows the spectral comparison between 2-HG and Gly simulated using ideal (gray) and fully localized simulations (green) and the spectrum acquired in the phantom test bottle containing 2mM 2-HG and 10mM Gly (black). Using PRESS localization, there is a loss of the H3/H3' resonance as shown in both the localized simulations and phantom data, which is in strong contrast to ideal simulations. This peak is preserved using semi-LASER at TE of 110 milliseconds, which generates near-identical spectral profiles across ideal, localized, and phantom data.

Comparing the fully localized 2-HG spectra with a simulated pulse-acquire experiment, the signal amplitude at 2.25 ppm is measured as 53.5% using PRESS and 37.9% using semi-LASER (neglecting T2 relaxation). At the 1.9 ppm resonance (optimized for in this study), this becomes 2.9% for PRESS and 36.4% for semi-LASER.

Sensitivity of 2-HG Detection

The *sensitivity* of both methods to detect 2-HG across a range of concentrations was assessed next in the phantom. Spectra were line-broadened (6 Hz) to match in vivo conditions. Figure 5A

shows the CRLB of fitting the acquired spectra with the simulated localized LCMoel basis. Both PRESS and semi-LASER maintain near-identical CRLBs of 2-HG fitting for concentrations >0.5mM, falling to 2% for 8mM of 2-HG (SNR: 57 semi-LASER; 64 PRESS). At 0.1mM, the CRLB after 128 averages is 53% and 19% for PRESS and semi-LASER, respectively. To further examine the sensitivity of the methods, data were split into averaged spectra containing 2, 4, 8, 16, 32, 64, and 128 transients. Figure 5A also shows the LCMoel CRLB output as a function of the acquired number of averages, using the 2mM 2-HG phantom bottle as an example. Both methods maintain identical relationships with an increasing number of spectral averages. Even with only 2 averages (SNR ~ 15), both methods fit 2-HG at 2mM with CRLBs of 15% ± 7% and 14% ± 6% for PRESS and semi-LASER, respectively.

Figure 5B shows the ratio of detected 2-HG to Gly with the LCMoel over the same concentration values without correcting for T2 differences. For concentrations >0.1mM (CRLBs <20%), both methods differed significantly in their estimation of 2-HG concentration ($P < .008$, paired t test) with average detection ratios of 76% ± 6% and 96% ± 6% of the true ratio for PRESS and semi-LASER, respectively.

Acquisition In Vivo

Data were then acquired in vivo and analyzed from our sample of 11 patients with glioma and 5 healthy controls using semi-LASER (TE = 110 milliseconds, $n = 11$ patients) and PRESS (TE = 97 milliseconds, $n = 7$ patients). The summary of these data for 2-HG detection is given in Table 1 (information on further metabolites is given in Supplementary Materials [3]).




Figure 5. Sensitivity of semi-LASER and PRESS for 2-HG detection in phantom. Cramér–Rao lower bound (CRLB) of the LC-Model fitting as a function of 2-HG concentration collected for 128 transients (A). Both methods show comparable errors across all concentration values. In addition, CRLBs are shown as a function of the number of acquired averages in a phantom bottle containing 2mM 2-HG. The ratio of detected 2-HG to Gly is plotted as a function of concentration compared with true concentration (B). Absolute values are not reported because of T2 decay time differences in phantom.

Figure 6 shows the immunohistochemistry and DNA-sequencing results from 3 patients. Further, 4 examples of the *in vivo* spectral quality along with the LCModel fits are shown in Figure 7—one example for each of the following: IDH1-mutant patient (P08); IDH-WT (P03), to be confirmed (TBC; P10), and healthy volunteer

(control; C01). These spectra are representative of the high spectral quality obtained with both sequences. In particular, the amplitude of the residual water peak is less than tNAA or tCr, and no significant lipid contamination was observed, owing to the use of outer volume suppression. This resulted in flat baselines over the analysis

Table 1. Summary of *in vivo* Data for 11 Glioma Patients and 5 Healthy Controls with 2-HG Concentrations (mM) and CRLBs Including PRESS were Obtained

ID	Sex/Age	Tumour Type/WHO Grade	IDH-Mutant	2HG (mM)			
				Semi-LASER		PRESS	
				Conc.	CRLB %	Conc.	CRLB %
P01	M/53	Glioblastoma/IV	IDH-WT	1.25	40	NA	
P02	F/37	Glioblastoma/IV	IDH-WT	0.88	34	0.00	999
P03	M/45	Oligodendroglioma/III	IDH-WT	1.17	115	1.55	87
P04	M/52	Astroglial Tumour/III	IDH1	3.87	15	NA	
P05	M/33	Anaplastic Astrocytoma/III	IDH1	0.59	68	NA	
P06	M/22	Diffuse Astrocytoma/II	IDH1	1.95	21	2.74	22
P07	F/26	Oligodendroglioma/II	IDH2	4.46	8	NA	
P08	F/56	Astrocytoma/III	IDH1 ^a	1.78	15	0.78	45
P09	F/44	TBC	TBC	1.94	16	1.63	69
P10	M/24	TBC	TBC	2.91	11	3.81	13
P11	M/36	TBC	TBC	6.33	8	6.06	8
C01	F/30	—	—	0.32	112	0	999
C02	M/35	—	—	0.43	103	0	999
C03	F/24	—	—	0.66	59	0	999
C04	F/25	—	—	0	999	0	999
C05	M/24	—	—	0.14	228	0	999

IDH1 or IDH2 indicates mutations in either enzyme.

^a denotes post-operative scan.

Abbreviations: TBC, To be confirmed; NA, Not Applicable (Data not acquired).




Figure 6. Tumor immunohistochemistry and sequencing. Hematoxylin and eosin (A, D, F); immunohistochemistry using anti-IDH1 R132H antibody (brown reaction product) (B, E, G); and PCR and direct sequencing of codon 132 of IDH1 (top trace) and R172 of IDH2 (bottom trace) (C, H). Case P01 (A, B, C): glioblastoma without IDH1 R132H mutation or IDH2 mutation; case P08 (D, E): astrocytoma with IDH1 R132H mutation; case P07 (F, G, H): oligodendroglioma without IDH1 R132H mutation but with IDH2 R172K mutation (P07; histological data previously published in the study by Emir et al.) (21); all scale bars are 100 μ m.

range of 0.5–4.2 ppm except in 1 patient (P06), for whom spectral analysis was restricted to 3.8 ppm.

The presence of the H3/H3' multiplet can be clearly seen in the raw IDH1 tumor spectrum (Figure 7) and in a further 6 patients (including the TBC patient, also shown in Figure 7) who underwent scanning with semi-LASER (Supplementary Materials [4]). The occurrence of this peak at 1.9 ppm, upfield of the NAA singlet at 2.01 ppm, gives in vivo 2-HG semi-LASER spectra a distinctive spectral profile and can be seen in the raw data even before the LCModel fitting.

In the 5 histologically confirmed IDH-mutated tumors, semi-LASER CRLBs of 2-HG fitting of $\leq 21\%$ were obtained in all but 1 patient (P05: 68%). For PRESS, only 1 data set has been histologically confirmed as IDH-mutated. Because of this low number, a comparison using conventional CRLB rejection thresholds would introduce bias. Therefore, the average 95% confidence interval for 2-HG in IDH-mutants was compared in patients who underwent scanning using both methods ($n = 2$) and concentrations of 1.3 ± 1.0 mM and 1.8 ± 0.7 mM for PRESS and semi-LASER, respectively, were found. If we include patients with IDH status yet to be confirmed in this analysis ($n = 5$), these confidence intervals become 2.8 ± 1.2 mM and 2.5 ± 0.7 mM for PRESS and semi-LASER, respectively. In both cases, detected concentrations are in agreement across methods; yet, the confidence intervals are considerably improved using the optimized semi-LASER. For the IDH-WT patients, the minimum fitted CRLB is 34% for semi-LASER and 87% for PRESS. In all

healthy controls, 2-HG remained correctly undetected (CRLBs, 999%) using PRESS and also with semi-LASER all CRLBs were $>100\%$, except 1 (minimum, 59%; maximum, 999%).

Thus, a patient (P10) (Figure 7) awaiting biopsy is predicted to be IDH-mutated given the low CRLB (11%) using semi-LASER and the clear peak in the spectrum at 1.9 ppm. Glu and Gln are detectable with both methods; however, Glu is detected with higher CRLBs using semi-LASER than PRESS. In addition, at 110 milliseconds, the Lac peak at 1.33 ppm is almost fully inverted for semi-LASER, which significantly aids in its fitting, generating much lower average CRLBs across all patients of $10 \pm 2\%$ compared with $21 \pm 8\%$ for PRESS.

Figure 8 shows the average correlation coefficients across all metabolite fittings and patients for each sequence. It can clearly be seen that using both sequences, the pairwise correlation coefficients between 2-HG and GABA are large (semi-LASER: $r_{2HG:GABA} = -0.55 \pm 0.26$; PRESS: $r_{2HG:GABA} = -0.53 \pm 0.14$). Similar measures of the correlation coefficients for Glu are as follows: semi-LASER: $r_{2HG:Glu} = 0.14 \pm 0.16$; PRESS: $r_{2HG:Glu} = 0.31 \pm 0.19$, and for Gln, the coefficients are as follows: semi-LASER: $r_{2HG:Gln} = 0.01 \pm 0.09$; PRESS: $r_{2HG:Gln} = -0.02 \pm 0.06$.

DISCUSSION

The results reveal that an optimized semi-LASER MRS sequence offers high sensitivity and localization for in vivo detection of 2-HG, characteristic of IDH-mutated brain tumors, at 3 T. The use of a long TE (110 milliseconds) not only enables direct





Figure 7. Example of in vivo spectral acquisition using semi-LASER and PRESS. Data shown are from IDH-mutant (IDH1), To be confirmed (TBC), IDH wild-type (IDH-WT), and healthy volunteer (control). The LCModel fits of 2-HG, Glu, Gln, GABA, and lactate (Lac) shown with CRLBs (%) are given next to corresponding spectra. The green arrow in IDH1 indicates 2-HG peak visible with semi-LASER. Major peaks of NAA, total choline (tCho), and total creatine (tCr) are labeled on the IDH1 spectra for reference.

detection of the H3/H3' multiplet of 2-HG at 1.9 ppm in the in vivo spectra but also generates reduced fitting correlations with overlapping Glu and Gln resonances and improved fitting of Lac compared with an existing long-TE PRESS sequence (16). These improvements promise a more robust assignment of such metabolites for the investigation of tumor metabolism in vivo.

The need to consider the effect of localization on the spectral pattern of the strongly coupled spin system of 2-HG is strikingly shown using 2D simulations (Figure 4). It has been shown that the loss of the H3/H3' multiplet with PRESS, as eluded to by Choi et al. (17), is because of a significantly large compartmental artifact within the voxel, which arises from long



J-evolution times under enhanced chemical shift displacement from narrow-bandwidth RF pulses. This effect manifests as the formation of a large negatively phased signal component in the PRESS voxel, opposite to that expected using ideal pulses, which has a deleterious effect on any positive signal contribution from other compartments. The effect of signal cancellation using PRESS has been well documented for several spin systems (18, 28), and it is known that for strongly coupled metabolites in particular, coherence transfer and spin evolution become harder to predict (19). Comparatively, semi-LASER suffers from considerably reduced compartmental artifacts, with an overall 2-HG spectral pattern that is similar to that expected using ideal hard pulses (Figure 4). This finding is similar to that reported by Kaiser et al. (30), namely that using broadband adiabatic localization on strongly coupled spins retains much of the ideal spectral pattern. In this study, the chemical shift displacement across a single dimension (measured between the H_3/H_3' peak and the carrier frequency at 2.7 ppm) is 8.2% of the nominal voxel size using the Refoman6 pulses in PRESS and 1.9% using the 5.5 kHz HS4 R25 adiabatic pulse in semi-LASER. The chemical shift displacement can be improved even further, by refocusing using frequency offset corrected inversion (FOCI) or gradient offset independent adiabatic (GOIA) (36, 37) pulses, with the potential benefit of reducing total specific absorption rate (SAR) (38). Even when the B_1 requirement of semi-LASER is reduced to match that of PRESS, using longer-duration pulses (10.2 milliseconds, maximum $B_1 = 13.4 \mu T$), the signal amplitude at 1.9 ppm is still ~ 12 times larger because of the increased bandwidth (2.46 kHz) of the broadband refocusing pulses. It is worth noting from a practical viewpoint that a strong chemical shift displacement artifact not only results in signal attenuation, as discussed above, but also causes metabolite measurement displacement from the prescribed voxel location, which is potentially problematic in the spatially heterogeneous environment of a tumor.

Our optimization on the H_3/H_3' 2-HG, Gln, and Glu overlaps resulted in a TE which is 13 milliseconds longer than that for PRESS. Considering J-modulation alone, this resulted in H_4/H_4' (2.25 ppm) 2-HG peak amplitudes to be 29% smaller using semi-LASER than using PRESS. This discrepancy did not appear to affect semi-LASER detection in the phantom. Indeed, CRLBs were similar for both sequences as a function of 2HG

concentration and the number of acquired averages. When comparing the detected 2HG-to-Gly ratios in the phantom with true values, semi-LASER appeared to detect more accurate concentrations than PRESS, although both methods tended to underestimate. This is in contrast with the results of the study by Choi et al. who correctly detected true phantom concentrations within the same range using the PRESS 97 millisecond sequence (17). In the study presented here, only relative concentration ratios in the phantom are reported, as a correction for T2 relaxation was not performed. T2 relaxation values of 2-HG and Gly in the phantom would be difficult to estimate, yet it would account for the underestimation of concentration in both methods resulting from fitting on reduced signal amplitudes. The observation that concentrations were underestimated more using a shorter-TE PRESS sequence than semi-LASER could be explained by the fact that during localization with 4 refocusing pulses in semi-LASER, apparent signal decay from T2 relaxation is somewhat reduced (39). Micheali et al. have measured apparent T2 values for NAA and Cr at 4 T using CP-LASER and CP-PRESS and found values almost twice as large (40).

Although the H_4/H_4' (2.25 ppm) resonance is smaller in amplitude with semi-LASER, the presence of the H_3/H_3' resonance at 1.9 ppm helps with detection. This is particularly true at very small concentrations of 0.1mM, where the CRLB was 19% for semi-LASER and 53% for PRESS. Although not realistically detectable in vivo, detection at these low concentrations in the phantom indicate that semi-LASER may offer improvements on detectability at small concentrations of 2-HG. It is hoped that this increase in sensitivity would benefit measurement from small tumor volumes, which have proven problematic for 2-HG detection in a recent study using PRESS (TE = 97 milliseconds) (41).

In the in vivo acquisitions, the presence of the H_3/H_3' peak is clearly apparent alongside the NAA singlet in the IDH1-mutated patient shown in Figure 7 (green arrow) and also in 6 other patients (3 IDH-mutant, 3 TBC; Supplementary Materials [4]). The identification of this peak in the raw spectra presents a clear benefit to rapidly ascertain IDH status by obviating the need for more complex fitting algorithms. The proximity of H_3/H_3' to NAA at 2.01 ppm is 14.1 Hz at 3 T; thus, if metabolite line widths were around this order of magnitude or NAA concentrations were high (for example, in lower-grade gliomas)

(42), this peak would become visually unresolvable. However, in all our patients, reasonable line widths were obtained and an inspection of the average pairwise fitting correlations between total NAA and 2-HG revealed very low average coefficients ($r_{2HG:tNAA} = 0.09$) (Figure 8).

The narrower confidence interval on the estimation of 2-HG concentration in IDH-mutated tumors using semi-LASER (1.8 ± 0.7 mM) compared with that using PRESS (1.3 ± 1.0 mM) is also maintained after the inclusion of patients whose IDH mutation status is yet to be confirmed (PRESS: 2.8 ± 1.2 mM; semi-LASER: 2.5 ± 0.7 mM). A direct comparison between semi-LASER and PRESS detection rates, using conventional CRLB rejection thresholds, was not appropriate in this study (low number of patients). However, the use of 95% confidence intervals, derived from CRLBs, revealed that estimated 2-HG concentrations using semi-LASER are in agreement with those using PRESS and that semi-LASER yielded more consistent concentrations as determined by the narrower confidence intervals. Therefore, this optimized semi-LASER sequence may offer an increase in the reliability of 2-HG estimation, although investigation on a larger number of IDH patients is needed.

A correlational analysis revealed that, on average, the pairwise fitting correlation is larger for Glu using PRESS ($r_{2HG:Glu} = 0.31$) than for that using semi-LASER ($r_{2HG:Glu} = 0.14$). This is attributed to the additional “degree of fitting” on the H3/H3' resonance where Glu overlap is reduced. However, CRLBs of fitting for Glu across patients and controls were higher for semi-LASER (29%) than for PRESS (18%). The reason for this might be 2-fold. First, accurate detection of low Glu concentrations using semi-LASER could result in larger CRLBs of detection. It is important to note that larger CRLBs do not necessarily equate to inestimable metabolite concentrations, and care should be taken to reject results with larger CRLBs as an inability to detect (43). Interestingly, a recent *in vitro* study on the metabolic profile of IDH mutants revealed a decrease in Glu levels (44). Second, a large 2-HG concentration, which lies on top of reduced Glu and Gln resonances at 1.9 ppm, could lead to an underestimation of these lower-concentration metabolites. Further investigation in phantom may help understand the ability of the proposed method to determine Glu concentrations.

A limitation of this study is the reporting of absolute metabolite levels quantified using an internal water reference within tumor voxels. Factors which will affect this quantification method, such as regional differences in water concentration and metabolite relaxation in the heterogeneous tumor environment, are difficult to estimate in practice during patient studies. Apparent metabolite T2 decay rates are variable with both tumor grade and MRS sequence used, and have the potential to complicate the quantification of metabolite concentrations (45). There is a need for accurate measurement of T2 relaxation rates of 2-HG and other metabolites using semi-LASER at 3 T.

The low CRLBs ($\leq 40\%$) of 2-HG in 2 IDH-WT tumors using semi-LASER indicate that this method may lack specificity in certain cases. The reason for these false-positive assignments may be because of the failure of the LCModel to fit GABA instead of 2-HG. Indeed, for one particular patient (P02; IDH-WT), 2-HG was fitted with CRLB of 34%, yet GABA was not fit

at all. The pairwise correlation coefficient of fitting between 2-HG and GABA is large and negative ($r_{2HG:GABA} = -0.55$) for semi-LASER, suggesting that 2-HG and GABA are “stealing” signals from each other. This could explain the lower average CRLBs for 2-HG in healthy volunteers in whom semi-LASER was used. It is worth noting that PRESS is also not immune to this effect given its correlation of $r_{2HG:GABA} = -0.53$.

The unambiguous assignment of the H3/H3' peak also relies on the fact that GABA concentration at this position is relatively small given its resonance at 1.89 ppm; 2-HG concentrations typically range from 5–35 μ M in gliomas (2); therefore, 2-HG tends to dominate the spectrum. However, the presence of GABA in human gliomas is unclear. One *ex vivo* study of several tumor types did not report any GABA detection (46), while a separate *ex vivo* study found an increase in GABA in low-grade, IDH-mutated gliomas (47). In the *in vivo* work done by Choi et al., GABA was not detectable or existed at a very low levels across subjects (17). In a recent study, using an optimized PRESS sequence at 7 T, Ganji et al. examined the effect of overlaps by removing 2-HG from the fitting basis, which resulted in a considerable influence on the detection of GABA along with Glu and Gln (48). However, removing GABA from the basis set may lead to substandard metabolite fitting for early-stage tumors or voxels containing healthy tissue. It would be an interesting avenue for future research to use GABA-specific MRS sequences to assess concentrations of this metabolite *in vivo* in different tumor types.

A significant benefit of the 110 millisecond optimized TE of semi-LASER is that Lac was quantifiable across all patients and controls with significantly reduced CRLBs compared with PRESS ($P = 0.038$, paired *t* test). At this TE, the Lac doublet at 1.3 ppm is almost fully inverted ($1/J = 144$ millisecond; 49), which allowed accurate estimation with semi-LASER. Importantly, the acquisition of Lac along with 2-HG is an interesting prospect because of its role in tumor metabolism (50). Similar to the recent observations at 7 T (21), elevated Lac levels were detected across all patients with tumors compared with controls ($2.3\times$, $P = 0.003$, paired *t* test). Furthermore, the single confirmed IDH2 patient in the current study had the largest detected 2-HG concentration (4.46mM) relative to others, lending support to the putative link between 2-HG levels and IDH mutation type mentioned previously (21). However, more reliable acquisition of 2-HG with lower CRLBs of fitting, as well as other tumor metabolites such as Gly and glutathione, may better be achieved at ultrahigh fields (≥ 7 T) (13, 21, 48, 51), where gains from spectral resolution reduce problems with overlap. In summary, the detection of multiple tumor-related metabolites, along with accurate estimations of 2-HG, could help build a more integrated picture of cellular metabolic processes *in vivo* and lead to further stratification of patients. For 3 T semi-LASER at 110 milliseconds, wider, cross-centre studies are required on larger patient groups to fully assess its ability to achieve this goal.

CONCLUSION

An optimized semi-LASER sequence at 3 T with long TE (110 milliseconds) is capable of a robust 2-HG detection in IDH patients. Because of its reduced chemical shift displacement

artifact compared with that of an existing PRESS localization scheme, compartmental artifacts are considerably reduced, leading to the complete refocusing of a resonance at 1.9 ppm. This distinct peak is clearly observable in the in vivo spectrum and together with reduced Glu and Gln overlaps, aids in the assignment of 2-HG. Lactate is also easier to detect with this method compared with PRESS because of the slightly longer TE. Because novel therapeutic approaches to glioma treatment are currently being developed, such as the targeted inhibition of

IDH-mutants (52), it is anticipated that this method will be hugely beneficial for accurate in vivo assessment of tumor status and glioma progression at 3 T through robust 2-HG and Lac estimation.

Supplemental Materials

Supplementary Materials [1]–[4]: <http://dx.doi.org/10.18383/j.tom.2016.00139.sup.01>

ACKNOWLEDGMENTS

The authors would like to acknowledge the following: ESRC fully funded studentship (A Berrington), HDH Wills 1965 Charitable Trust and NIHR Oxford Biomedical Research Centre (NL Voets), the Oxford Brain Bank, the Medical Research Council, Brains for Dementia Research, the Wellcome Trust (UE Emir), the Dunhill Medical Trust (P Jezard), and the NIHR Oxford Biomedical Research Centre. The authors would also like to

thank Dr Clark Lemke for discussions involving the implementation of density matrix simulations.

Disclosure: No disclosures to report.

Conflict of Interest: None reported.

REFERENCES

1. Parsons DW, Jones S, Zhang X, Lin J-C, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu I-M, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam D, Tekleab H, Diaz L, Hartigan J, Smith DR, Strausberg RL, Marie SKN, Shinjo SMO, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. An integrated genomic analysis of human glioblastoma multiforme. *Science*. 2008; 321(5897):1807–1812.
2. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liao LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. *Nature*. 2009; 462(7274):739–744.
3. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batnina-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD. IDH1 and IDH2 mutations in gliomas. *N Engl J Med*. 2009;360(8):765–773.
4. Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Nounshahr M, Laird PW, Cherniack AD, Akbani R, Huse JT, Ciriello G, Poisson LM, Barnholtz-Sloan JS, Berger MS, Brennan C, Colen RR, Colman H, Flanders AE, Giannini C, Grifford M, Iavarone A, Jain R, Joseph I, Kim J, Kasaiya K, Mikkelsen T, Murray BA, O'Neill BP, Pachter L, Parsons DW, Sougnez C, Sulman EP, Vandenbergh SR, Van Meir EG, von Deimling A, Zhang H, Crain D, Lau K, Mallery D, Morris S, Paulauskis J, Penny R, Shelton T, Sherman M, Yena P, Black A, Bowen J, Dicostanzo K, Gastier-Foster J, Leraas KM, Lichtenberg TM, Pierson CR, Ramirez NC, Taylor C, Weaver S, Wise L, Zmuda E, Davidson T, Demchok JA, Eley G, Ferguson ML, Hutter CM, Mills Shaw KR, Ozenberger BA, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Ayala B, Baboud J, Chudamani S, Jensen MA, Liu J, Pihl T, Raman R, Wan Y, Wu Y, Ally A, Auman JT, Balasundaram M, Balu S, Baylin SB, Beroukhi M, Bootwalla MS, Bowlby R, Bristow CA, Brooks D, Butterfield Y, Carlsen R, Carter S, Chin L, Chu A, Chuah E, Cibulskis K, Clarke A, Coetzee SG, Dhalla N, Fennell T, Fisher S, Gabriel S, Getz G, Gibbs R, Guin R, Hadjipanayis A, Hayes DN, Hinoue T, Hoadley K, Holt RA, Hoyle AP, Jefferys SR, Jones S, Jones CD, Kucherlapati R, Lai PH, Lander E, Lee S, Lichtenstein L, Ma Y, Maglinte DT, Mahadeshwar HS, Marra MA, Mayo M, Meng S, Meyerson ML, Mieczkowski PA, Moore RA, Mose LE, Mungall AJ, Pantazi A, Parfenov M, Park PJ, Parker JS, Perou CM, Protopopov A, Ren X, Roach J, Sabedot TS, Schein J, Schumacher SE, Seidman JG, Seth S, Shen H, Simons JV, Sipahimalani P, Soloway MG, Song X, Sun H, Tabak B, Tam A, Tan D, Tang J, Thiessen N, Triche T Jr, Van Den Berg DJ, Veluvolu U, Waring S, Weisenberger DJ, Wilkerson MD, Wong T, Wu J, Xi L, Xu AW, Yang L, Zack TI, Zhang J, Aksoy BA, Arachchi H, Benz C, Bernard B, Carlin D, Cho J, DiCara D, Frazer S, Fuller GN, Gao J, Gehlenborg N, Haussler D, Heiman DI, Iype L, Jacobsen A, Ju Z, Katzman S, Kim H, Knijnenburg T, Kreisberg RB, Lawrence MS, Lee W, Leinonen K, Lin P, Ling S, Liu W, Liu Y, Liu Y, Lu Y, Mills G, Ng S, Noble MS, Paull E, Rao A, Reynolds S, Saksena G, Sanborn Z, Sander C, Schultz N, Senbabaoglu Y, Shen R, Shmulevich I, Sinha R, Stuart J, Sumer SO, Sun Y, Tasman N, Taylor BS, Voet D, Weinhold N, Weinstein JN, Yang D, Yoshihara K, Zheng S, Zhang W, Zou L, Abel T, Sadeghi S, Cohen ML, Eschbacher J, Hattab EM, Raghunathan A, Schniederjan MJ, Aziz D, Barnett G, Barrett W, Bigner DD, Boice L, Brewer C, Calatuzzolo C, Campos B, Carlotti CG Jr, Chan TA, Cuppini L, Curley E, Cuzzubbo S, Devine K, DiMeco F, Duell R, Elder JB, Fehrenbach A, Finocchiaro G, Friedman W, Fulop J, Gardner J, Hermes B, Herold-Mende C, Jungk C, Kendler A, Lehman NL, Lipp E, Liu O, Mandi R, McGraw M, McLendon R, McPherson C, Neder L, Nguyen P, Noss A, Nunziata R, Ostrom QT, Palmer C, Perin A, Pollo B, Potapov A, Potapova O, Rathmell WK, Rotin D, Scarpace L, Schilero C, Senecal K, Shimmel K, Shurkhay V, Sifri S, Singh R, Sloan AE, Smolenski K, Staugaitis SM, Steele R, Thorne L, Tirapelli DP, Unterberg A, Vallurupalli M, Wang Y, Warnick R, Williams F, Wolinsky Y, Bell S, Rosenberg M, Stewart C, Huang F, Grimsby JL, Radenbaugh AJ, Zhang J. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. *N Engl J Med*. 2015;372(26):2481–2498.
5. Yen KE, Bittinger MA, Su SM, Fantin VR. Cancer-associated IDH mutations: biomarker and therapeutic opportunities. *Oncogene*. 2010;29(49):6409–6417.
6. Turkalp Z, Karamchandani J, Das S. IDH mutation in glioma: new insights and promises for the future. *JAMA Neurol*. 2014;71(10):1319–1325.
7. Kalinina J, Carroll A, Wang L, Yu Q, Mancheno DE, Wu S, Liu F, Ahn J, He M, Mao H, Van Meir EG. Detection of “oncometabolite” 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma. *J Mol Med*. 2012;90(10):1161–1171.
8. Bal D, Gryff-Keller A. 1H and 13C NMR study of 2-hydroxyglutaric acid and its lactone. *Magn Reson Chem*. 2002;40(8):533–536.
9. Gordon RE, Ordidge RJ. Volume selection for high resolution NMR studies. In: *Proceedings of the International Society for Magnetic Resonance in Medicine: Third Annual Meeting August 13–17, New York, NY; 1984:257–305*. DOI: 10.1002/mrmp.22419840107.
10. Bottomley PA. Spatial localization in NMR spectroscopy in vivo. *Ann N Y Acad Sci*. 1987;508:333–348.
11. Pope WB, Prins RM, Albert Thomas M, Nagarajan R, Yen KE, Bittinger M a, Salamon N, Chou AP, Yong WH, Soto H, Wilson N, Driggers E, Jang HG, Su SM, Schenkein DP, Lai A, Cloughesy TF, Kornblum HI, Wu H, Fantin VR, Liao LM. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. *J Neurooncol*. 2012;107(1):197–205.
12. Heo H, Kim S, Lee HH, Cho HR, Xu WJ, Lee S-H, Park C-K, Park S, Choi SH, Kim H. On the utility of short echo time (TE) single voxel 1H-MRS in non-invasive detection of 2-hydroxyglutarate (2HG): Challenges and potential improvement illustrated with animal models using MRUI and LCMModel. *PLoS One*. 2016;11(1): e0147794.
13. Bisdas S, Chadzynski GL, Braun C, Schittenhelm J, Skardelly M, Hagberg GE, Ethofer T, Pohmann R, Shajan G, Engelmann J, Tabatabai G, Ziemann U, Ernmann U, Scheffler K. MR spectroscopy for in vivo assessment of the oncometabolite 2-hydroxyglutarate and its effects on cellular metabolism in human brain gliomas at 9.4T. *J Magn Reson Imaging*. 2016. doi: 10.1002/jmri.25221. [Epub ahead of print].
14. Andronesi OC, Kim GS, Gerstner E, Batchelor T, Tzika AA, Fantin VR, Vander Heiden MG, Gregory Sorenson AG. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. *Sci Transl Med*. 2012;4(116):116ra4.

15. Carlsson A, Ljungberg M, Starck G, Forsell-Aronsson E. Degraded water suppression in small volume ¹H MRS due to localised shimming. *MAGMA*. 2011; 24(2):97–107.
16. Choi C, Ganji SK, DeBerardinis RJ, Hatanpaa KJ, Rakheja D, Kovacs Z, Yang X-L, Mashimo T, Raisanen JM, Marin-Valencia I, Pascual JM, Madden CJ, Mickey BE, Malloy CR, Bachoo RM, Maher EA. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. *Nat Med*. 2012;18(4):624–629.
17. Choi C, Ganji S, Hulsey K, Madan A, Kovacs Z, Dimitrov I, Zhang S, Pichumani K, Mendelsohn D, Mickey B, Malloy C, Bachoo R, DeBerardinis R, Maher E. A comparative study of short- and long-TE ¹H MRS at 3T for in vivo detection of 2-hydroxyglutarate in brain tumors. *NMR Biomed*. 2013;26(10):1242–1250.
18. Slotboom J, Mehlkopf AF, Bovee WMMJ. The effects of frequency-selective RF pulses on J-coupled spin- systems. *J Magn Reson*. 1994;1(108):38–50.
19. Thompson RB, Allen PS. Sources of variability in the response of coupled spins to the PRESS sequence and their potential impact on metabolite quantification. *Magn Reson Med*. 1999;41(6):1162–1169.
20. Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. *NMR Biomed*. 2000;13(3):129–153.
21. Emir UE, Larkin SJ, de Pennington N, Voets N, Plaha P, Stacey R, Al-Qahtani K, McCullagh J, Schofield CJ, Clare S, Jezzard P, Cadoux-Hudson T, Ansgore O. Noninvasive quantification of 2-hydroxyglutarate in human gliomas with IDH1 and IDH2 mutations. *Cancer Res*. 2016;76(1):43–49.
22. Berrington A, Voets N, Larkin SJ, de Pennington N, McCullagh J, Al-Qahtani K, Stacey R, Yildirim M, Jezzard P, Clare S, Schofield C, Ansgore O, Cadoux-Hudson T, Plaha P, Emir UE. Improved detection of 2-hydroxyglutarate with a broadband semi-LASER sequence at 3 T. In: *ESMRMB, 32nd Annual Scientific Meeting*, Edinburgh, UK; 2015:28(Suppl. 1), 277–418. DOI:10.1007/s10334-015-0489-0.
23. Scheenen TWJ, Klomp DWJ, Wijnen JP, Heerschap A. Short echo time ¹H-MRSI of the human brain at 3T with minimal chemical shift displacement errors using adiabatic refocusing pulses. *Magn Reson Med*. 2008;59(1):1–6.
24. Garwood M, Delabarre L. The return of the frequency sweep: designing adiabatic pulses for contemporary NMR. *J Magn Reson*. 2001;153(2):155–177.
25. Soher BJ, Semanchuk P, Todd D, Steinberg J, Young K. VeSPA: Integrated applications for RF pulse design, spectral simulation and MRS data analysis. In: *ISMRM. Montreal*; 2011:1410.
26. Yablonskiy DA, Neil JJ, Raichle ME, Ackerman JJH. Homonuclear J coupling effects in volume localized NMR spectroscopy: pitfalls and solutions. *Magn Reson Med*. 1998;39(2):169–178.
27. Marshall I, Wild J. A systematic study of the lactate lineshape in PRESS-localized proton spectroscopy. *Magn Reson Med*. 1998;40(1):72–78.
28. Maudsley A, Govindaraju V, Young K, Aygula ZK, Pattany PM, Soher BJ, Matson GB. Numerical simulation of PRESS localized MR spectroscopy. *J Magn Reson*. 2005;173(1):54–63.
29. Young K, Matson GB, Govindaraju V, Maudsley AA. Spectral simulations incorporating gradient coherence selection. *J Magn Reson*. 1999;152:146–152.
30. Kaiser LG, Young K, Matson GB. Numerical simulations of localized high field ¹H MR spectroscopy. *J Magn Reson*. 2008;195(1):67–75.
31. Shah S, Kellman P, Greiser A, Weale PJ, Zuehlisdorff S, Jerecic R. Rapid fieldmap estimation for cardiac shimming. *Proc Int Soc Magn Reson Med*. 2009;17:566.
32. Tkáč I, Gruetter R. Methodology of ¹H NMR spectroscopy of the human brain at very high magnetic fields. *Appl Magn Reson*. 2005;29(1):139–157.
33. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. *Magn Reson Med*. 1993;30(6):672–679.
34. Madan A, Ganji SK, An Z, Choe KS, Pinho MC, Bachoo RM, Maher EM, Choi C. Proton T2 measurement and quantification of lactate in brain tumors by MRS at 3 Tesla in vivo. *Magn Reson Med*. 2015;73(6):2094–2099.
35. Ganji SK, Banerjee A, Patel AM, Zhao YD, Dimitrov IE, Browning JD, Sherwood Brown E, Maher EA, Choi C. T2 measurement of J-coupled metabolites in the human brain at 3T. *NMR Biomed*. 2012;25(4):523–529.
36. Ordidge RJ, Wylezinska M, Hugg JW, Butterworth E, Franconi F. Frequency offset corrected inversion (FOCI) pulses for use in localized spectroscopy. *Magn Reson Med*. 1996;36(4):562–566.
37. Tannús A, Garwood M. Adiabatic pulses. *NMR Biomed*. 1997;10:423–434.
38. Andronesi OC, Ramadan S, Ratai EM, Jennings D, Mountford CE, Greogry Sorensen A. Spectroscopic imaging with improved gradient modulated constant adiabaticity pulses on high-field clinical scanners. *J Magn Reson*. 2010;203(2):283–293.
39. Deelchand DK, Henry PG, Marjańska M. Effect of Carr-Purcell refocusing pulse trains on transverse relaxation times of metabolites in rat brain at 9.4 Tesla. *Magn Reson Med*. 2015;73(1):13–20.
40. Michaeli S, Garwood M, Zhu XH, Delabarre L, Andersen P, Adriany G, Merkle H, Ugurbil K, Chen W. Proton T2 relaxation study of water, N-acetylaspartate, and creatine in human brain using Hahn and Carr-Purcell spin echoes at 4T and 7T. *Magn Reson Med*. 2002;47(4):629–633.
41. de la Fuente MI, Young RJ, Rubel J, Rosenblum M, Tisnado J, Briggs S, Arevalo-Perez J, Cross JR, Campos C, Straley K, Zhu D, Dong C, Thomas A, Omuro AA, Nolan CP, Pentsova E, Kaley TJ, OH JH, Noeske R, Maher E, Choi C, Gutin PH, Holodny AI, Yen K, DeAngelis LM, Mellinghoff IK, Thakur SB. Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. *Neuro Oncol*. 2015;18(2):283–290.
42. Isobe T, Matsumura A, Anno I, Yoshizawa T, Nagatomo Y, Itai Y, Nose T. Quantification of cerebral metabolites in glioma patients with proton MR spectroscopy using T2 relaxation time correction. *Magn Reson Imaging*. 2002;20(4):343–349.
43. Kreis R. The trouble with quality filtering based on relative Cramér-Rao lower bounds. *Magn Reson Med*. 2016;75(1):15–18.
44. Ohka F, Ito M, Ranjit M, Senga T, Motomura A, Motomura K, Saito K, Kato K, Kato Y, Wakabayashi T, Soga T, Natsume A. Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation. *Tumour Biol*. 2014;35(6):5911–5920.
45. Li Y, Xu D, Ozturk-Isik E, Lupo JM, Chen AP, Vigneron DB, Nelson SJ. T1 and T2 metabolite relaxation times in normal brain at 3T and 7T. *J Mol Imaging Dynam*. 2013;S1(002).
46. Wright AJ, Fellows GA, Griffiths JR, Wilson M, Bell BA, Howe FA. Ex-vivo HRMAS of adult brain tumours: metabolite quantification and assignment of tumour biomarkers. *Mol Cancer*. 2010;9:66.
47. Elkhalel A, Jalbert LE, Phillips JJ, Yoshihara HAI, Parvataneni R, Srinivasan R, Bourne G, Berger MS, Chang SM, Cha S, Nelson SJ. Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. *Sci Transl Med*. 2012; 4(116):116ra5.
48. Ganji SK, An Z, Tiwari V, McNeil S, Pinho MC, Pan E, Mickey BE, Maher EA, Choi C. In vivo detection of 2-hydroxyglutarate in brain tumors by optimized point-resolved spectroscopy (PRESS) at 7T. *Magn Reson Med*. 2016. doi: 10.1002/mrm.26190. [Epub ahead of print].
49. Lange T, Dydak U, Roberts TPL, Rowley HA, Bjeljac M, Boesiger P. Pitfalls in lactate measurements at 3T. *AJNR Am J Neuroradiol*. 2006;27(4):895–901.
50. Emir UE, Larkin S, de Pennington N, Plaha P, Voets NL, McCullagh J, Stacey R, Jezzard P, Clare S, Schofield CJ, Cadoux-Hudson T, Ansgore O. Distinguishing the Chemical Signature of Different IDH Mutations in Brain Tumor Patients at 7 Tesla. In: *ISMRM. Singapore*; 2016.
51. Berrington A, Larkin SJ, de Pennington N, Voets NL, Plaha P, Stacey R, Al-Qahtani K, McCullagh J, Schofield C, Clare S, Jezzard P, Cadoux-Hudson T, Ansgore O, Emir UE. The benefits of in vivo 2-hydroxyglutarate detection using semi-LASER at 7T and 3T: a comparative study. In: *ISMRM. Singapore*; 2016.
52. Ledford H. Metabolic quirks yield tumour hope. *Nature*. 2014;508:158–159.